Genetic Screening Could Lead to ‘Eugenics 2.0’ — Experts Warn of Ethical Crisis
A controversial new genetic screening tool raises ethical concerns about eugenics and the value of human life.
4 min read
When Rachel Barkley was born, her parents had no way of knowing she would one day face a life-altering diagnosis of a rare spinal cord cancer. But if they had had the chance to choose her genetic makeup before birth, they would have done so — not to prevent illness, but to replace her with a different child altogether. This is the chilling future that companies like Orchid are now promising, using the language of science and progress to mask a troubling return to eugenics.
The Rise of Genetic Screening and Its Ethical Implications
Orchid, a biotech company, has recently gained attention for offering full genome sequencing of embryos, a form of preimplantation genetic screening that allows parents to select embryos based on genetic traits. CEO Noor Siddiqui has been vocal about the potential of such technology, stating in a TED Talk and on X that parents should consider whether they are willing to “optimize” their child’s genome to prevent conditions like Down syndrome or spinal cord cancer. Her words, though framed as compassionate, echo a darker history of eugenics.
Historically, eugenics was a pseudoscientific ideology that justified forced sterilizations and the elimination of individuals deemed “unfit” to reproduce. In 1927, the Supreme Court upheld this ideology in the case of Buck v. Bell, with Justice Oliver Wendell Holmes Jr. writing that “three generations of imbeciles are enough.” This ruling led to the forced sterilization of thousands of people, including poor women, Black Americans, and individuals with disabilities. The logic was simple but cruel: some lives were considered less valuable and thus less worthy of being passed on.
Modern Biotechnology and the Echoes of Eugenics
Today, the same logic is being rebranded under the guise of medical advancement. Siddiqui’s comments on genetic diseases like Down syndrome as a “typo” on DNA reflect a mindset that reduces human life to a series of genetic risk scores and health profiles. This perspective is not just speculative; it has real-world consequences. In Denmark, for instance, universal prenatal screening has nearly eliminated births of children with Down syndrome, raising concerns about the systematic exclusion of individuals with disabilities.
Such practices raise profound ethical questions. Is it morally acceptable to eliminate the risk of suffering by choosing not to have a child with a disability? Or does this cross the line into dehumanization? The article argues that the line is not blurry: alleviating suffering is one thing, but eliminating people who suffer is another. The article highlights the use of metrics like “quality-adjusted life years” (QALYs) in healthcare rationing, which place greater value on a year of life lived without disability than on the life of someone like Barkley. This system, the article warns, devalues disabled lives by treating them as less worth living.
The Broader Implications of Genetic Optimization
The ethical concerns extend beyond individual families. The article notes that the ideology of optimization is not limited to private choices but is also embedded in public policy. President Donald Trump’s “Most Favored Nation” drug pricing model, for example, is said to import QALY-based rationing into the U.S. healthcare system. This suggests that the pursuit of efficiency in healthcare is not just a private matter but a public policy issue with far-reaching implications.
Barkley’s personal experience underscores the human cost of such policies. She describes the daily struggles of living with a disabling condition, including the longing to run with her children and wake up without pain. Yet, she emphasizes that her life is worth living not because it is optimal, but because it is human. This perspective challenges the notion that human value can be measured by genetic perfection or health outcomes.
Rejecting the Narrative of Genetic Optimization
Companies like Orchid market genetic screening as a tool for empowerment, but the article argues that this narrative misses the fundamental truth: a child is not a startup to be optimized. The real measure of human progress, Barkley contends, is not how efficiently we prevent imperfection, but whether we can build a world that welcomes, supports, and dignifies all individuals, regardless of their genetic makeup.
The article concludes with a call to action, urging society to reject the ideology of optimization and to embrace the intrinsic worth of every human life. It warns that the future of genetic screening could lead to a new form of eugenics, one that is justified by the language of science and progress but rooted in the same dehumanizing logic that once justified forced sterilization.
Source: Daily Wire
